antibody-drug conjugates

Oncology

Are radiopharmaceuticals the next breakthrough in oncology?

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.

Oncology

Oncology market dominance: As easy as ADC?

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals.

Views & Analysis

Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug.

Events

HW191105 World ADC London banner design 740 X 400px

Partner Content

World ADC London 2020

Maximise the Therapeutic Index of Your ADC Pipeline

Are radiopharmaceuticals the next breakthrough in oncology?

Oncology market dominance: As easy as ADC?

Antibody-drug conjugates on the march

World ADC London 2020

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

antibody-drug conjugates

Editor's Picks